A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001) - Chen, Hua-Jun; Tu, Hai-Yan; Hu, Yanping; Fan, Yun; Wu, Guowu; Cang, Shundong; Yang, Yi; Yang, Nong; Ma, Rui; Jin, Gaowa; Xu, Ximing; Liu, Anwen; et al. (Journal of hematology and oncology, 2025)
Keywords: Adult; Aged; Anlotinib; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Blood vessels; Cancer Research; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Cell survival; Chemotherapy; Clinical medicine; Clinical trials; Disease control; Disease Progression; Drug dosages; EGFR mutation; Epidermal growth factor receptors; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Female; Gradual progression; Hematology; Humans; Indoles - administration & dosage; Indoles - adverse effects; Indoles - therapeutic use; Kinases; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Medicine; Medicine & Public Health; Middle Aged; Mutation; Non-small cell lung cancer; Non-small cell lung carcinoma; Oligo progression; Oncology; Oral administration; Patients; Pemetrexed; Product development; Progression-Free Survival; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Quinolines - administration & dosage; Quinolines - adverse effects; Quinolines - therapeutic use; Response rates; Small cell lung carcinoma; Toxicity; Tumors; Tyrosine kinase inhibitors; Young Adult; China; EGFR mutation; Oligo progression; Anlotinib; Gradual progression; Non-small cell lung cancer